Shed vs MedVi: Coaching and name-brand or low-cost semaglutide
Quick verdict: Shed vs MedVi
For patients deciding between Shed and MedVi, the core choice is coaching plus name-brand options (Shed) versus a lower promotional price and a fully online, no-clinic route for compounded semaglutide (MedVi). Early verdict: choose Shed if you want integrated coaching and access to both name-brand and compounded GLP-1; choose MedVi if you prioritize the lowest first-month price and a simple online process.
Start Shed 2-minute assessment
How they differ: five side-by-side points
| Criteria | Shed | MedVi |
|---|---|---|
| Starting price / promo | Compounded semaglutide starting at $199/month; 10% off your first month | Promotional first month $179 with fast, free shipping; ongoing months higher |
| Medication options | Offers both FDA-approved name-brand GLP-1 and compounded options | Clinically dosed compounded semaglutide only; no branded options published |
| Coaching and support | Integrated continuous coaching bundled into treatment | 24/7 support from certified medical professionals; simple online process |
| Process / visits | 2-minute approval assessment, clinician review before prescription | Simple online intake with no clinic visits and clinician review after checkout |
| Regulatory note | Compounded medications are not FDA-approved; name-brand options carry regulatory approval | Compounded medications are not FDA-approved; produced in FDA-regulated facilities but not FDA-evaluated |
Pricing and promotions compared
Shed lists compounded semaglutide starting at $199/month and compounded tirzepatide starting at $299/month, and it advertises 10% off your first month. MedVi advertises a winter promotional first month at $179, including fast, free shipping, but notes that the ongoing standalone month can be $299 and three-month plans are available at $649. The comparison here is promotional-first-month versus bundled coaching and name-brand access; Shed’s 10% off applies to a first month, while MedVi’s $179 rate is explicitly a promotional first-month price and may increase thereafter.
Medication choices: name-brand and tirzepatide vs semaglutide only
Shed is notable for offering both FDA-approved name-brand GLP-1 medications and compounded alternatives on one platform, letting patients choose based on budget and preference. It also lists compounded tirzepatide injections starting at $299/month. MedVi markets clinically dosed compounded semaglutide only and does not list tirzepatide or branded Wegovy/Ozempic as part of its standard offering. MedVi states its compounded semaglutide uses the same active ingredient as branded products, while Shed emphasizes the regulatory assurance of name-brand options alongside compounded alternatives.
Compare Shed medication options
Coaching, support, and the care model
Shed integrates continuous coaching into its plans and positions coaching as part of treatment rather than an add-on. That is presented as a differentiator for patients who want behavioral support alongside medication. MedVi highlights 24/7 support from certified medical professionals and emphasizes a simple online process with no clinic visits required. Both platforms require clinician review and issue prescriptions only after a provider determines treatment is appropriate.
Process and eligibility
Shed uses a 2-minute assessment to check eligibility, followed by clinician review. MedVi uses a simple online intake with no clinic visits and an OpenLoop Health or affiliated clinician review; MedVi notes its web assessment does not itself create a doctor-patient relationship and that clinicians retain discretion to prescribe. Both providers state that compounded medications are prepared by licensed pharmacies and that results may vary.
Regulatory and outcome notes to keep in mind
Both Shed and MedVi include regulatory language that compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. Shed explicitly offers FDA-approved name-brand GLP-1s in addition to compounded products; MedVi emphasizes compounded semaglutide produced in FDA-regulated facilities but notes the medications themselves are not FDA-approved. Outcome statements on both sites include qualifiers that results vary and depend on adherence and clinician guidance.
Final comparison and recommendation
In short: Shed vs MedVi breaks down to broader medication choice plus integrated coaching (Shed) versus the lowest promotional entry price and a fully online, no-clinic path for compounded semaglutide (MedVi). If your priority is access to name-brand GLP-1s and ongoing coaching, Shed matches that need. If you want the lowest advertised first-month price and fast, free shipping with a simple online intake, MedVi delivers that option.
Choose Shed if…
you want both FDA-approved name-brand GLP-1 options and compounded alternatives on one platform, integrated continuous coaching bundled into treatment, and a fast 2-minute assessment with a 10% first-month offer.
Choose MedVi if…
you prioritize the lowest promotional first-month price at $179 with fast, free shipping, a simple online intake with no clinic visits, and 24/7 certified medical support for compounded semaglutide.